OGN Organon & Co. (OGN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001821825
C-suite buying · 1Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
251
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced
What the filings say about OGN
Insiders, 180 days
-$200.3K net sold
1 buyer · 2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2026-08-05
Planned sales (Form 144), 90 days
$200.3K
1 notice
Organon & Co. insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Organon & Co. insiders sold a net $200.3K of stock across 12 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 79.9% of the 18,474 shares held after it.
- No other insider sold within 30 days.
- 251 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Head of Mfg & Supply Drinane Juliana Papa sold about $200.3K of OGN on Aug 5, 2026; 251 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- No other insider sold within 30 days.
- 251 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP and Corporate Controller Holzbaur Lynette sold about $353.1K of OGN on May 6, 2026, the largest insider sale at the company on our record; 251 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 50.0% of the 52,850 shares held after it.
- No other insider bought within 30 days.
- 251 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP and Corporate Controller Holzbaur Lynette bought about $353.1K of OGN on May 6, 2026; 251 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 14, 2025.
- The trade is 84.0% of the 77,869 shares held after it.
- No other insider bought within 30 days.
- 251 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chair COX CARRIE SMITH bought about $501.6K of OGN on Nov 12, 2025, the largest insider purchase at the company on our record; 251 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 12,469 shares held after it.
- 5 other insiders bought within 30 days.
- 251 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director COX CARRIE SMITH bought about $100.6K of OGN on May 14, 2025; 5 other insiders bought within 30 days and 251 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$200.3K over 180 days
-$200.3K over 90 days
more than 52% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
251 funds bought in last quarter
more than 93% of Pharma & Biotech
Revenue
-2.9% year over year
below 60% of Pharma & Biotech
Margin
3.0% net margin
more than 76% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.8% of the float short (float per yahoo 2026-10-26) · 9.1 days to cover · settled 2026-09-30
more than 61% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch OGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+55.1%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns OGN: institutional holders (13F)
13F holdings, latest reported quarter
32,056,866 sh
$434.0M
18,100,000 sh
$245.1M
15,132,118 sh
$204.9M
11,909,865 sh
$161.3M
9,659,371 sh
$130.8M
Congress trades in OGN
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-08-05 · disclosed 5 days later
$1,001 - $15,000
Sold 2026-08-05 · disclosed 7 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
OGN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JULIANA P DRINANE
Filed 2026-08-05
$200.3K
OGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
NexPoint Event Driven Fund
$2.3M position · as of 2026-06-30
3.1%
NYLIM Merger Arbitrage ETF
$6.8M position · as of 2026-07-31
2.7%
Nexpoint Merger Arbitrage Fund
$36.6M position · as of 2026-06-30
2.5%
ProShares Merger ETF
$376.2K position · as of 2026-05-31
2.4%
AltShares Merger Arbitrage ETF
$2.4M position · as of 2026-05-31
2.3%
AltShares Event-Driven ETF
$266.8K position · as of 2026-05-31
2.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Organon & Co. Employee Political Action Committee
Cycle 2026 · $63K spent
$106.8K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Kevin Ali
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$17.1M
$16.4M
$4.4M
+4705%
+30%
2023
$14.8M
-$553.8K
$4.1M
+4271%
+26%
2022
$13.5M
$11.7M
$4.1M
+7865%
+21%
2021
$18.6M
$14.3M
$5.3M
+8272%
+15%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $200.3K sold by insiders over 180 days, 251 funds added last quarter, $200.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
OGN financials
Revenue growth
-2.9%
XBRL, annual
Net margin
3.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM OGN
| FY Dec 2025 | $6.2B |
| FY Dec 2024 | $6.4B |
| FY Dec 2023 | $6.3B |
| FY Dec 2022 | $6.2B |
| FY Dec 2021 | $6.3B |
| Jun 2026 | $1.6B |
| Mar 2026 | $1.5B |
| Dec 2025 | $1.5B |
| Sep 2025 | $1.6B |
| Jun 2025 | $1.6B |
| Mar 2025 | $1.5B |
| Dec 2024 | $1.6B |
| Sep 2024 | $1.6B |
At each fiscal year end
Single quarter
Net margin, TTM
+3.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM OGN
| FY Dec 2025 | +3.0% |
| FY Dec 2024 | +13.5% |
| FY Dec 2023 | +16.3% |
| FY Dec 2022 | +14.9% |
| FY Dec 2021 | +21.4% |
| Jun 2026 | +6.9% |
| Mar 2026 | +10.0% |
| Dec 2025 | -13.6% |
| Sep 2025 | +10.0% |
| Jun 2025 | +9.1% |
| Mar 2025 | +5.8% |
| Dec 2024 | +6.8% |
| Sep 2024 | +22.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$567.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM OGN
| FY Dec 2025 | $538.0M |
| FY Dec 2024 | $764.0M |
| FY Dec 2023 | $548.0M |
| FY Dec 2022 | $662.0M |
| FY Dec 2021 | n/a |
| Jun 2026 | $65.0M |
| Mar 2026 | $188.0M |
| Dec 2025 | $96.0M |
| Sep 2025 | $218.0M |
| Jun 2025 | $181.0M |
| Mar 2025 | $43.0M |
| Dec 2024 | $335.0M |
| Sep 2024 | $99.0M |
At each fiscal year end
Single quarter
Debt to equity
8.50x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity OGN
| FY Dec 2025 | 11.49x |
| FY Dec 2024 | 18.81x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 8.50x |
| Mar 2026 | 9.49x |
| Dec 2025 | 11.49x |
| Sep 2025 | 9.74x |
| Jun 2025 | 12.14x |
| Mar 2025 | 16.52x |
| Dec 2024 | 18.81x |
| Sep 2024 | 17.75x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.09x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt OGN
| FY Dec 2025 | 0.08x |
| FY Dec 2024 | 0.11x |
| FY Dec 2023 | 0.09x |
| FY Dec 2022 | 0.10x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.09x |
| Mar 2026 | 0.10x |
| Dec 2025 | 0.08x |
| Sep 2025 | 0.11x |
| Jun 2025 | 0.09x |
| Mar 2025 | 0.10x |
| Dec 2024 | 0.11x |
| Sep 2024 | 0.11x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+24.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity OGN
| FY Dec 2025 | +30.6% |
| FY Dec 2024 | +429.9% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +67.9% |
| Jun 2026 | +24.0% |
| Mar 2026 | +34.0% |
| Dec 2025 | +30.6% |
| Sep 2025 | +71.6% |
| Jun 2025 | +159.6% |
| Mar 2025 | +254.2% |
| Dec 2024 | +429.9% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets OGN
| FY Dec 2025 | +1.4% |
| FY Dec 2024 | +6.9% |
| FY Dec 2023 | +8.9% |
| FY Dec 2022 | +8.5% |
| FY Dec 2021 | +13.0% |
| Jun 2026 | +1.6% |
| Mar 2026 | +1.9% |
| Dec 2025 | +1.4% |
| Sep 2025 | +3.8% |
| Jun 2025 | +5.5% |
| Mar 2025 | +6.0% |
| Dec 2024 | +6.9% |
| Sep 2024 | +10.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital OGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed OGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
17.63x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing OGN
| FY Dec 2025 | 9.96x |
| FY Dec 2024 | 4.49x |
| FY Dec 2023 | 3.61x |
| FY Dec 2022 | 7.78x |
| FY Dec 2021 | 5.72x |
| Jun 2026 | 17.36x |
| Mar 2026 | 6.37x |
| Dec 2025 | 9.96x |
| Sep 2025 | 5.59x |
| Jun 2025 | 3.61x |
| Mar 2025 | 5.19x |
| Dec 2024 | 4.49x |
| Sep 2024 | 3.80x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$11.0B
market value at close 2026-10-23 on 2026-07-24 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value OGN
| FY Dec 2025 | $9.9B |
| FY Dec 2024 | $12.0B |
| FY Dec 2023 | $11.8B |
| FY Dec 2022 | $15.3B |
| FY Dec 2021 | $16.1B |
| Jun 2026 | $11.0B |
| Mar 2026 | $9.0B |
| Dec 2025 | $9.9B |
| Sep 2025 | $10.9B |
| Jun 2025 | $10.8B |
| Mar 2025 | $12.2B |
| Dec 2024 | $12.0B |
| Sep 2024 | $12.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+15.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield OGN
| FY Dec 2025 | +28.9% |
| FY Dec 2024 | +19.9% |
| FY Dec 2023 | +14.9% |
| FY Dec 2022 | +9.3% |
| FY Dec 2021 | n/a |
| Jun 2026 | +15.9% |
| Mar 2026 | +43.8% |
| Dec 2025 | +28.9% |
| Sep 2025 | +28.0% |
| Jun 2025 | +26.1% |
| Mar 2025 | +20.2% |
| Dec 2024 | +19.9% |
| Sep 2024 | +15.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -71%, PEG needs growth
PEG, trailing OGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.32x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $6.2B | $6.4B | $6.3B | $6.2B |
| Gross profit | $3.3B | $3.7B | $3.7B | $3.9B |
| Net income | $187.0M | $864.0M | $1.0B | $917.0M |
| EPS (diluted) | 0.72 | 3.33 | 3.99 | 3.59 |
| Operating cash flow | $700.0M | $939.0M | $799.0M | $858.0M |
| Cash | $574.0M | $675.0M | $693.0M | $706.0M |
| Long-term debt | $8.6B | $8.9B | $8.8B | $8.9B |
| Dividends paid | $88.0M | $297.0M | $294.0M | $290.0M |
SEC XBRL, fiscal years, as known on 2026-10-27
OGN Stock Sonar score 6/7 axes
Find similar shapesCompareOGN ranks highest on profitability (87th percentile) and institutional and government (61st), and lowest on risk and compliance (27th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
OGN filings, in plain words
Are Organon & Co. insiders buying or selling OGN?
In the 180 days to 2026-10-27, Organon & Co. insiders were net sellers, a net $200.3K: $353.1K of purchases and $553.4K of sales reported on Form 4, by 1 buyer and 2 sellers.
Have members of Congress traded OGN?
Yes. In the year to 2026-10-27, 0 House members disclosed buying OGN and 1 House member disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-08-05.
Are there planned insider sales of OGN?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $200.3K of stock; the latest, by JULIANA P DRINANE, was filed 2026-08-05.
Read the full summary
In the 180 days to 2026-10-27, Organon & Co. insiders were net sellers of OGN, a net $200.3K across purchases and sales reported on Form 4 by 1 buyer and 2 sellers. In the year to 2026-10-27, 0 members of Congress disclosed buying OGN and 1 member disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-08-05. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $200.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
